The Role of LMO2 in Development and in T Cell Leukemia After Chromosomal Translocation or Retroviral Insertion
Open Access
- 1 January 2006
- journal article
- review article
- Published by Elsevier in Molecular Therapy
- Vol. 13 (1), 15-25
- https://doi.org/10.1016/j.ymthe.2005.09.010
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trialBlood, 2005
- Activation of the T-Cell OncogeneLMO2after Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2004
- LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1Science, 2003
- A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2003
- RNA interferenceNature, 2002
- Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic proteinJournal of Molecular Biology, 2002
- The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodiesJournal of Molecular Biology, 2002
- The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug targetOncogene, 2002
- Identification of genes potentially involved in LMO2-induced leukemogenesisLeukemia, 2000
- The rhombotin gene family encode related LIM-domain proteins whose differing expression suggests multiple roles in mouse developmentJournal of Molecular Biology, 1992